Curative Biotechnology, Inc. (CUBT)

OTCMKTS: CUBT · Delayed Price · USD
0.0190
-0.0010 (-5.00%)
Nov 29, 2022 2:45 PM EST - Market closed
-5%
Market Cap 9.68M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 537.88M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 801,544
Open 0.022
Previous Close 0.02
Day's Range 0.0185 - 0.022
52-Week Range n/a
Beta 272.39
Analysts n/a
Price Target n/a
Earnings Date n/a

About CUBT

Curative Biotechnology, Inc. operates as a development-stage biomedical company. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include IMT504, a novel immune therapy to treat rabies and an adjuvant for vaccines; CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor; and Metformin Reformulation for the tre... [Read more]

Industry Biotechnology
Founded 1995
Employees 4
Stock Exchange OTCMKTS
Ticker Symbol CUBT
Full Company Profile

News

Curative Biotechnology Announces Intent to Uplist to NYSE American Exchange

Boca Raton, FL, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for r...

2 months ago - GlobeNewsWire

Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors

Appointment of Independent Director Builds Upon Biotech Expertise

5 months ago - GlobeNewsWire

Curative Biotechnology, Inc. Names Cary Sucoff to Board of Directors

Appointment of Independent Director Adds to Financial Expertise on Board BOCA RATON, Fla. , May 12, 2022 /PRNewswire/ -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a ...

6 months ago - PRNewsWire

Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors

Appointment of Independent Director Adds to Financial Expertise on Board

6 months ago - GlobeNewsWire

Curative Biotechnology Announces Toxicology Studies Under Good Laboratory Practices (GLP) for Metformin Eye Drop Form...

National Eye Institute (NEI) to Collaborate with Curative Biotechnology under Cooperative Research and Development Agreement (CRADA)    BOCA RATON, Fla. , May 3, 2022 /PRNewswire/ -- Curative Biotechnol...

6 months ago - PRNewsWire

Curative Biotechnology Announces Good Laboratory Practice (GLP) Toxicology Studies with Metformin Eye Drop Formulatio...

National Eye Institute (NEI) to Collaborate with Curative Biotechnology under Cooperative Research and Development Agreement (CRADA)

6 months ago - GlobeNewsWire

Curative Biotechnology Announces Cooperative Research and Development Agreement(CRADA) with the National Eye Institut...

BOCA RATON, Fla. , March 21, 2022 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative" or the "Company"), a development-stage biomedical company focused on novel treatments for rare dise...

8 months ago - PRNewsWire

Curative Biotechnology Announces Cooperative Research and Development Agreement (CRADA) with the National Eye Institu...

Emily Y. Chew, M.D. of the National Eye Institute Assigned Principal Investigator

8 months ago - GlobeNewsWire

[UPDATED] CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATME...

Company's First I n -license Pipeline P roduct to E nter P re- clinical S tudies

1 year ago - GlobeNewsWire

CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACU...

Company's First I n -license Pipeline P roduct to E nter P re- clinical S tudies

1 year ago - GlobeNewsWire

CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO

Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients , Late-Stage Rabies Therapeutic and Age-related Macular Degeneration

1 year ago - GlobeNewsWire

Curative Biotechnology Announces IMT504 License For Development Of Proprietary Next-Gen COVID-19 Vaccine

BOCA RATON, Fla., Oct. 7, 2021 /PRNewswire/ -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative Biotech" or the "Company") announced today that the Company has reached agreement with Mid-Atlantic Bio...

1 year ago - PRNewsWire

Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board

Company's Clinical Program for CD56 Monoclonal Antibody Drug Conjugate for Treatment of Glioblastoma to Benefit from Exper tise in Neurobiology

1 year ago - GlobeNewsWire

Curative Biotechnology, Inc. Appoints Marc Drimer, CPA to Board of Directors as Independent Director and Chairman of ...

Boca Raton, FL, July 15, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage biomedical company focused on novel therapies for rar...

1 year ago - GlobeNewsWire

Curative Biotechnology, Inc. Files 2021 First Quarter Financials and Issues Letter to Shareholders

Boca Raton, FL, May 25, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company targeting novel treatments for rar...

1 year ago - GlobeNewsWire

Curative Biotechnology, Inc. Announces Trading Symbol Change to “CUBT”

Kapil Bharti, Ph.D. and Dimiter Dimitrov, Ph.D. Join Scientific and Clinical Advisory Board

1 year ago - GlobeNewsWire